Biotech News

Biomea Fusion to Participate in Upcoming Investor Conferences

Biomea Fusion (BMEA)Biomea FusionCompany update

SAN CARLOS, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare

Related news

Biomea Fusion

Metabolic Disease Company Biomea Fusion develops small molecules intended to restore metabolic function in diabetes and obesity. Icovamenib Icovamenib is a covalent menin inhibitor being evaluated for potential restoration of insulin-producing beta-cell function in type 1 and type 2 diabetes. COVALENT Program COVALENT-211 and...

Recent company news

Stock data

Close
0.59 USD
Market cap
99.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States